MicroTransponder’s Post

...and here is how to briefly present a FIRST, the first mini-oscillometer, a revolutionary diagnostic device !... in French... ..MGC Diagnostics International, MGC Diagnostics, Restech - Respiratory Technology

Shares in EBR Systems, Inc. (ASX:EBR) are up more than 100% over the last year as the company continues to revolutionise cardiac rhythm management with its wireless WiSE CRT System used to treat heart rhythm diseases. Ahead of appearing at Wholesale Investor and CAPITALHQ Emergence 2025 event Andrew Shute, Senior Vice President of Business Development at EBR Systems Inc (ASX:EBR) joins The Stock Network’s Lel Smits GAICD. ❤️🩹 Problems and causes of traditional cardiac rhythm management systems 🫀 Advantages of WiSE CRT System 🌍 Global opportunity & US sales for cardiac rhythm management Watch the full interview ⚡https://lnkd.in/gST-f2BK

Saw this post on X today. Found it interesting as when we were being trained on the effects of SGLT2is when I came onboard in 2013, we were trained on the differences in the diameters between the afferent and efferent arterioles, these differences resulted in the hemodynamic changes seen with: *RAASis *SGLT2is *nsMRAS *other agents impacting the neurohormonal axis. Every new is old again…

William Gray, MD, is lead author of a study on the Neuroguard IEP system for the treatment of narrowing of the carotid artery in patients at high risk of serious adverse reactions to surgical removal of plaque in the artery. The PERFORMANCE II trial, for which Dr. Gray was co-national principal investigator, found an extremely low rate of major adverse events, demonstrating its safety, effectiveness and durability. LIMR was a trial site for PERFORMANCE II. The system comprises an integrated filter, stent and balloon all on the same catheter. It allows for a rapid and efficient procedure providing double filtration, which results in highly effective protection from clotting. https://bit.ly/3CffH2o

Editor’s Choice: Ah Young Lee and colleagues describe "Efficacy and safety of MC-003 solution for endoscopic mucosal or submucosal resection: a prospective, multicenter, randomized, triple-blinded, parallel-group, phase III study." Find it at https://lnkd.in/g3Ruytf6. Also read the editorial by Emmanuel Coronel, "A new kid on the 'bloc'? A case for another submucosal injection agent for endoscopic resection of early gastric neoplasms."

Did you know that 80 million people have glaucoma globally? Stay up-to-date on the latest in glaucoma with the 2024 Glaucoma Report! Get the report now for further insights into how your colleagues approach glaucoma management for 2024. From implantable sustained-release drug delivery systems to diagnostic confidence, we've got you covered. Learn from the collective wisdom of the eyecare community. https://hubs.ly/Q02D3LlP0

The Importance of Consistency in DIR In radiation therapy, consistent deformable image registration (DIR) is key to better outcomes. Variable results can affect dose distribution, compromising target coverage and increasing the risk to healthy tissue. That’s why Autofuse is a game-changer—it’s FULLY AUTOMATED and delivers CONSISTENT RESULTS EVERY TIME. No more worrying about variability in multiple registrations. Ever been frustrated by inconsistent DIR outcomes? Autofuse ensures precision and peace of mind. Contact us via info@pymedix.com to learn more about the most innovative FDA cleared radiation treatment planning aid in the market.

Recently, Dr. John Gaughen performed the first carotid stenting procedure at Centra with a newly approved FDA device. The Neuroguard IEP System is a unique 3-in-1 carotid stenting device that combines a high-performance stent, an integrated dilation balloon and an integrated filter. The system streamlines the carotid stent procedure by reducing steps and making it safer by capturing emboli that traditional embolic protection systems do not. Clinical studies of the Neuroguard IEP System have consistently recorded unprecedented low event rates – zero major strokes, zero neurologic deaths, and zero stent thrombosis at 30 days and 1 year. Dr. Gaughen trained on this new procedure in Nashville, TN, and we are so thankful that he brought this new technology back to Centra! 

News of the week: 12-month results for Phase 2 trial evaluating heat-therapy system for MGD, topline results from targeted photobiomodulation for treatment of progressive myopia, enrollment complete in Phase 3 trials to evaluate new wet AMD therapy, and more. Read all about it in EyeWorld Weekly

#CME Opportunity: This accredited activity created with Duke Heart and Med-IQ presents a detailed patient case analysis designed to enhance awareness of the importance of differentiating the mechanism of mitral valve regurgitation (primary vs secondary) to determine appropriate management approaches. 🔗 https://bit.ly/4bo3Jj6